Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christopher D. Paddock is active.

Publication


Featured researches published by Christopher D. Paddock.


Clinical Microbiology Reviews | 2005

Tick-Borne Rickettsioses around the World: Emerging Diseases Challenging Old Concepts

Philippe Parola; Christopher D. Paddock; Didier Raoult

SUMMARY During most of the 20th century, the epidemiology of tick-borne rickettsioses could be summarized as the occurrence of a single pathogenic rickettsia on each continent. An element of this paradigm suggested that the many other characterized and noncharacterized rickettsiae isolated from ticks were not pathogenic to humans. In this context, it was considered that relatively few tick-borne rickettsiae caused human disease. This concept was modified extensively from 1984 through 2005 by the identification of at least 11 additional rickettsial species or subspecies that cause tick-borne rickettsioses around the world. Of these agents, seven were initially isolated from ticks, often years or decades before a definitive association with human disease was established. We present here the tick-borne rickettsioses described through 2005 and focus on the epidemiological circumstances that have played a role in the emergence of the newly recognized diseases.


Clinical Microbiology Reviews | 2013

Update on Tick-Borne Rickettsioses around the World: a Geographic Approach

Philippe Parola; Christopher D. Paddock; Cristina Socolovschi; Marcelo B. Labruna; Oleg Mediannikov; Tahar Kernif; Mohammad Yazid Abdad; John Stenos; Idir Bitam; Pierre-Edouard Fournier; Didier Raoult

SUMMARY Tick-borne rickettsioses are caused by obligate intracellular bacteria belonging to the spotted fever group of the genus Rickettsia. These zoonoses are among the oldest known vector-borne diseases. However, in the past 25 years, the scope and importance of the recognized tick-associated rickettsial pathogens have increased dramatically, making this complex of diseases an ideal paradigm for the understanding of emerging and reemerging infections. Several species of tick-borne rickettsiae that were considered nonpathogenic for decades are now associated with human infections, and novel Rickettsia species of undetermined pathogenicity continue to be detected in or isolated from ticks around the world. This remarkable expansion of information has been driven largely by the use of molecular techniques that have facilitated the identification of novel and previously recognized rickettsiae in ticks. New approaches, such as swabbing of eschars to obtain material to be tested by PCR, have emerged in recent years and have played a role in describing emerging tick-borne rickettsioses. Here, we present the current knowledge on tick-borne rickettsiae and rickettsioses using a geographic approach toward the epidemiology of these diseases.


Clinical Infectious Diseases | 2004

Rickettsia parkeri: A Newly Recognized Cause of Spotted Fever Rickettsiosis in the United States

Christopher D. Paddock; John W. Sumner; James A. Comer; Sherif R. Zaki; Cynthia S. Goldsmith; Jerome Goddard; Susan L. F. McLellan; Cynthia L. Tamminga; Christopher A. Ohl

Ticks, including many that bite humans, are hosts to several obligate intracellular bacteria in the spotted fever group (SFG) of the genus Rickettsia. Only Rickettsia rickettsii, the agent of Rocky Mountain spotted fever, has been definitively associated with disease in humans in the United States. Herein we describe disease in a human caused by Rickettsia parkeri, an SFG rickettsia first identified >60 years ago in Gulf Coast ticks (Amblyomma maculatum) collected from the southern United States. Confirmation of the infection was accomplished using serological testing, immunohistochemical staining, cell culture isolation, and molecular methods. Application of specific laboratory assays to clinical specimens obtained from patients with febrile, eschar-associated illnesses following a tick bite may identify additional cases of R. parkeri rickettsiosis and possibly other novel SFG rickettsioses in the United States.


PLOS Pathogens | 2009

Isolation of Genetically Diverse Marburg Viruses from Egyptian Fruit Bats

Jonathan S. Towner; Brian R. Amman; Tara K. Sealy; Serena A. Carroll; James A. Comer; Alan Kemp; Robert Swanepoel; Christopher D. Paddock; Stephen Balinandi; Marina L. Khristova; Pierre Formenty; César G. Albariño; David Miller; Zachary Reed; John Kayiwa; James N. Mills; Deborah Cannon; Patricia W. Greer; Emmanuel Byaruhanga; Eileen C. Farnon; Patrick Atimnedi; Samuel Okware; Edward Katongole-Mbidde; Robert Downing; Jordan W. Tappero; Sherif R. Zaki; Thomas G. Ksiazek; Stuart T. Nichol; Pierre E. Rollin

In July and September 2007, miners working in Kitaka Cave, Uganda, were diagnosed with Marburg hemorrhagic fever. The likely source of infection in the cave was Egyptian fruit bats (Rousettus aegyptiacus) based on detection of Marburg virus RNA in 31/611 (5.1%) bats, virus-specific antibody in bat sera, and isolation of genetically diverse virus from bat tissues. The virus isolates were collected nine months apart, demonstrating long-term virus circulation. The bat colony was estimated to be over 100,000 animals using mark and re-capture methods, predicting the presence of over 5,000 virus-infected bats. The genetically diverse virus genome sequences from bats and miners closely matched. These data indicate common Egyptian fruit bats can represent a major natural reservoir and source of Marburg virus with potential for spillover into humans.


Clinical Microbiology Reviews | 2003

Ehrlichia chaffeensis: a Prototypical Emerging Pathogen

Christopher D. Paddock; James E. Childs

SUMMARY Ehrlichia chaffeensis is an obligately intracellular, tick-transmitted bacterium that is maintained in nature in a cycle involving at least one and perhaps several vertebrate reservoir hosts. The moderate to severe disease caused by E. chaffeensis in humans, first identified in 1986 and reported for more than 1,000 patients through 2000, represents a prototypical “emerging infection.” Knowledge of the biology and natural history of E. chaffeensis, and of the epidemiology, clinical features, and laboratory diagnosis of the zoonotic disease it causes (commonly referred to as human monocytic ehrlichiosis [HME]) has expanded considerably in the period since its discovery. In this review, we summarize briefly the current understanding of the microbiology, pathogenesis, and clinical manifestations associated with this pathogen but focus primarily on discussing various ecological factors responsible for the recent recognition of this important and potentially life-threatening tick-borne disease. Perhaps the most pivotal element in the emergence of HME has been the staggering increases in white-tailed deer populations in the eastern United States during the 20th century. This animal serves as a keystone host for all life stages of the principal tick vector (Amblyomma americanum) and is perhaps the most important vertebrate reservoir host for E. chaffeensis. The contributions of other components, including expansion of susceptible human populations, growth and broadening geographical distributions of other potential reservoir species and A. americanum, and improvements in confirmatory diagnostic methods, are also explored.


The New England Journal of Medicine | 1999

Ehrlichia ewingii, a Newly Recognized Agent of Human Ehrlichiosis

Richard S. Buller; Max Q. Arens; S. Paul Hmiel; Christopher D. Paddock; John W. Sumner; Yasuko Rikihisa; Ahmet Unver; Monique Gaudreault-Keener; Farrin A. Manian; Allison M. Liddell; Nathan Schmulewitz; Gregory A. Storch

BACKGROUND Human ehrlichiosis is a recently recognized tick-borne infection. Four species infect humans: Ehrlichia chaffeensis, E. sennetsu, E. canis, and the agent of human granulocytic ehrlichiosis. METHODS We tested peripheral-blood leukocytes from 413 patients with possible ehrlichiosis by broad-range and species-specific polymerase-chain-reaction (PCR) assays for ehrlichia. The species present were identified by species-specific PCR assays and nucleotide sequencing of the gene encoding ehrlichia 16S ribosomal RNA. Western blot analysis was used to study serologic responses. RESULTS In four patients, ehrlichia DNA was detected in leukocytes by a broad-range PCR assay, but not by assays specific for E. chaffeensis or the agent of human granulocytic ehrlichiosis. The nucleotide sequences of these PCR products matched that of E. ewingii, an agent previously reported as a cause of granulocytic ehrlichiosis in dogs. These four patients, all from Missouri, presented between May and August 1996, 1997, or 1998 with fever, headache, and thrombocytopenia, with or without leukopenia. All had been exposed to ticks, and three were receiving immunosuppressive therapy. Serum samples obtained from three of these patients during convalescence contained antibodies that reacted with E. chaffeensis and E. canis antigens in a pattern different from that of humans with E. chaffeensis infection but similar to that of a dog experimentally infected with E. ewingii. Morulae were identified in neutrophils from two patients. All four patients were successfully treated with doxycycline. CONCLUSIONS These findings provide evidence of E. ewingii infection in humans. The associated disease may be clinically indistinguishable from infection caused by E. chaffeensis or the agent of human granulocytic ehrlichiosis.


American Journal of Pathology | 2010

2009 Pandemic Influenza A (H1N1): Pathology and Pathogenesis of 100 Fatal Cases in the United States

Wun-Ju Shieh; Dianna M. Blau; Amy M. Denison; Marlene DeLeon-Carnes; Patricia Adem; Julu Bhatnagar; John W. Sumner; Lindy Liu; Mitesh Patel; Brigid Batten; Patricia W. Greer; Tara Jones; Chalanda Smith; Jeanine Bartlett; Jeltley L. Montague; Elizabeth H. White; Dominique Rollin; Rongbao Gao; Cynthia Seales; Heather Jost; Maureen G. Metcalfe; Cynthia S. Goldsmith; Charles D. Humphrey; Ann Schmitz; Clifton P. Drew; Christopher D. Paddock; Timothy M. Uyeki; Sherif R. Zaki

In the spring of 2009, a novel influenza A (H1N1) virus emerged in North America and spread worldwide to cause the first influenza pandemic since 1968. During the first 4 months, over 500 deaths in the United States had been associated with confirmed 2009 pandemic influenza A (H1N1) [2009 H1N1] virus infection. Pathological evaluation of respiratory specimens from initial influenza-associated deaths suggested marked differences in viral tropism and tissue damage compared with seasonal influenza and prompted further investigation. Available autopsy tissue samples were obtained from 100 US deaths with laboratory-confirmed 2009 H1N1 virus infection. Demographic and clinical data of these case-patients were collected, and the tissues were evaluated by multiple laboratory methods, including histopathological evaluation, special stains, molecular and immunohistochemical assays, viral culture, and electron microscopy. The most prominent histopathological feature observed was diffuse alveolar damage in the lung in all case-patients examined. Alveolar lining cells, including type I and type II pneumocytes, were the primary infected cells. Bacterial co-infections were identified in >25% of the case-patients. Viral pneumonia and immunolocalization of viral antigen in association with diffuse alveolar damage are prominent features of infection with 2009 pandemic influenza A (H1N1) virus. Underlying medical conditions and bacterial co-infections contributed to the fatal outcome of this infection. More studies are needed to understand the multifactorial pathogenesis of this infection.


Clinical Infectious Diseases | 2008

Rickettsia parkeri Rickettsiosis and Its Clinical Distinction from Rocky Mountain Spotted Fever

Christopher D. Paddock; Richard W. Finley; Cynthia S. Wright; Howard N. Robinson; Barbara J. Schrodt; Carole C. Lane; Okechukwu Ekenna; Mitchell Blass; Cynthia L. Tamminga; Christopher A. Ohl; Susan L. F. McLellan; Jerome Goddard; Robert C. Holman; John J. Openshaw; John W. Sumner; Sherif R. Zaki; Marina E. Eremeeva

BACKGROUND Rickettsia parkeri rickettsiosis, a recently identified spotted fever transmitted by the Gulf Coast tick (Amblyomma maculatum), was first described in 2004. We summarize the clinical and epidemiological features of 12 patients in the United States with confirmed or probable disease attributable to R. parkeri and comment on distinctions between R. parkeri rickettsiosis and other United States rickettsioses. METHODS Clinical specimens from patients in the United States who reside within the range of A. maculatum for whom an eschar or vesicular rash was described were evaluated by > or =1 laboratory assays at the Centers for Disease Control and Prevention (Atlanta, GA) to identify probable or confirmed infection with R. parkeri. RESULTS During 1998-2007, clinical samples from 12 patients with illnesses epidemiologically and clinically compatible with R. parkeri rickettsiosis were submitted for diagnostic evaluation. Using indirect immunofluorescence antibody assays, immunohistochemistry, polymerase chain reaction assays, and cell culture isolation, we identified 6 confirmed and 6 probable cases of infection with R. parkeri. The aggregate clinical characteristics of these patients revealed a disease similar to but less severe than classically described Rocky Mountain spotted fever. CONCLUSIONS Closer attention to the distinct clinical features of the various spotted fever syndromes that exist in the United States and other countries of the Western hemisphere, coupled with more frequent use of specific confirmatory assays, may unveil several unique diseases that have been identified collectively as Rocky Mountain spotted fever during the past century. Accurate assessments of these distinct infections will ultimately provide a more valid description of the currently recognized distribution, incidence, and case-fatality rate of Rocky Mountain spotted fever.


Emerging Infectious Diseases | 2010

Astrovirus Encephalitis in Boy with X-linked Agammaglobulinemia

Phenix Lan Quan; Thor A. Wagner; Thomas Briese; Troy R. Torgerson; Mady Hornig; Alla Tashmukhamedova; Cadhla Firth; Gustavo Palacios; Ada Baisre-de-Leon; Christopher D. Paddock; Stephen K. Hutchison; Michael Egholm; Sherif R. Zaki; James E. Goldman; Hans D. Ochs; W. Ian Lipkin

Unbiased pyrosequencing detected an astrovirus after conventional methods failed to identify the causative agent.


Clinical Infectious Diseases | 2001

Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in Persons Coinfected with Human Immunodeficiency Virus

Christopher D. Paddock; Scott M. Folk; G. Merrill Shore; Linda J. Machado; Mark M. Huycke; Leonard N. Slater; Allison M. Liddell; Richard S. Buller; Gregory A. Storch; Thomas P. Monson; David Rimland; John W. Sumner; Joseph Singleton; Karen C. Bloch; Yi-Wei Tang; Steven M. Standaert; James E. Childs

The clinical course and laboratory evaluation of 21 patients coinfected with human immunodeficiency virus (HIV) and Ehrlichia chaffeensis or Ehrlichia ewingii are reviewed and summarized, including 13 cases of ehrlichiosis caused by E. chaffeensis, 4 caused by E. ewingii, and 4 caused by either E. chaffeensis or E. ewingii. Twenty patients were male, and the median CD4(+) T lymphocyte count was 137 cells/microL. Exposures to infecting ticks were linked to recreational pursuits, occupations, and peridomestic activities. For 8 patients, a diagnosis of ehrlichiosis was not considered until > or =4 days after presentation. Severe manifestations occurred more frequently among patients infected with E. chaffeensis than they did among patients infected with E. ewingii, and all 6 deaths were caused by E. chaffeensis. Ehrlichiosis may be a life-threatening illness in HIV-infected persons, and the influence of multiple factors, including recent changes in the epidemiology and medical management of HIV infection, may increase the frequency with which ehrlichioses occur in this patient cohort.

Collaboration


Dive into the Christopher D. Paddock's collaboration.

Top Co-Authors

Avatar

Sherif R. Zaki

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John W. Sumner

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Wun-Ju Shieh

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Cynthia S. Goldsmith

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Dianna M. Blau

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

William L. Nicholson

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Amy M. Denison

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jerome Goddard

Mississippi State University

View shared research outputs
Researchain Logo
Decentralizing Knowledge